Joshua Lukenbill is an Oncology physician affiliated with Iowa Oncology Research Association. OpenAlex indexes 15 publications with 203 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 SW Magazine Rd
Ankeny, IA 500232977
Telephone
515-282-2921Provider last certified this registry record 18 Nov 2025.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
- Genentech USA, Inc.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
46.5%RANK Ligand Inhibitor46%Denosumab100%Part B, office-administered≥13 patientsXanthine oxidase inhibitor0.5%Allopurinol100%Part D<11 patientsCancer & immunology
15.5%Aromatase Inhibitor6.5%Anastrozole67%Letrozole29%Exemestane4%Part D<11 patientsKinase inhibitor3.6%Calquence42%Imbruvica20%Sprycel14%Brukinsa13%Jakafi11%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
9.9%Serotonin-3 Receptor Antagonist6%Ondansetron hydrochloride59%Ondansetron Hcl34%Ondansetron Odt7%Part D + Part B≥60 patientsProton pump inhibitor2%Omeprazole55%Pantoprazole Sodium45%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2022 per NIH RePORTER. The latest:
- Iowa-Wide Oncology Research Coalition (I-WORC)
Iowa Oncology Research Association
FY2022$1,300,000UG1CA189816 - Iowa-Wide Oncology Research Coalition (I-WORC)
Iowa Oncology Research Association
FY2021$1,225,688UG1CA189816
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”